SI
SI
discoversearch

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor.  We ask that you disable ad blocking while on Silicon Investor in the best interests of our community.  If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.
Biotech / Medical : Apricus Biosciences
 Public ReplyPrvt ReplyMark as Last ReadFilePrevious 10Next 10PreviousNext  
To: phoenix_rising who wrote (1892)4/29/2016 12:58:37 AM
From: mokelumne river  Read Replies (1) of 2026
 
PR, it has always puzzled me why an outfit like Takeda, obviously a Japanese pharma, got the license to the UK. Equally puzzling is why Takeda didn't get or press hard for a license for other EU countries...it never seemed to me worth it to license only one country. And why didn't Takeda seek the license for Japan?

Regardless, I agree with you that if Vitaros was flying off the shelves in the UK as Takeda would have liked, Takeda would have kept it. However, I really wonder if reimbursement is that big a deal. After all, the issue here is the ability to have sex for crying out loud. And there are plenty of men out there for whom the cost of Vitaros is less than the cost of a Starbuck's habit or a tobacco habit.

Quite frankly, I would not have been surprised to see the termination of the agreement with Sandoz in light of all of its problems. Takeda is a surprise. Maybe the silver lining is that Ferring will get its feet wet marketing Vitaros in preparation for marketing in Latin America. Just rambling...
Report TOU ViolationShare This Post
 Public ReplyPrvt ReplyMark as Last ReadFilePrevious 10Next 10PreviousNext  

HomeMailHotSubjectMarksPeopleMarksKeepersSettings
Terms Of UseContact UsCopyright/IP PolicyPrivacy PolicyAbout UsFAQAdvertise on SI
© 2025 Knight Sac Media.  Data provided by Twelve Data, Alpha Vantage, and CityFALCON News